Literature DB >> 22460158

Quantitative approaches to dopaminergic brain imaging.

K Tatsch1, G Poepperl.   

Abstract

During the last three decades dopaminergic brain imaging has emerged from a dedicated research tool to a widespread and routinely used application. The rationale behind this development is on the one hand the well known pathologic involvement of the dopaminergic pathway in various neuro-psychiatric diseases, and on the other hand the increasing availability of specific radioligands for picking up pre- and postsynaptic dopaminergic key functions. In particular the commercial availability of SPECT tracers but also the growing number of positron emission tomography/computed tomography (PET/CT) imaging devices has contributed to the steadily increasing number of diagnostic applications. In an era aiming for accurate diagnosis in the early and even preclinical stage of disease, refined methodologies are required to detect even subtle changes. In this context quantification of dopaminergic functions more and more gains importance. Whereas earlier visual assessment was considered sufficient to characterize findings, today refined quantitative tools have the potential to deliver information beyond. This review briefly addresses the development of quantitative methods for dopaminergic brain imaging, from simple manual ratio based applications to various automated methodologies, some of them including tools for correction of physical parameters such as scatter and septal penetration and partial volume effects. Voxel based analysis methods will be covered and also kinetic analyses will be briefly touched. The main focus is directed at SPECT rather than PET methodologies due to the clinical impact of the first. Finally, some thoughts regarding the impact of standardization and harmonization of protocols for imaging and processing will be discussed, including the use of normal data bases for reference.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22460158

Source DB:  PubMed          Journal:  Q J Nucl Med Mol Imaging        ISSN: 1824-4785            Impact factor:   2.346


  13 in total

1.  Examining endogenous dopamine in treated schizophrenia using [¹¹C]-(+)-PHNO positron emission tomography: A pilot study.

Authors:  Fernando Caravaggio; Carol Borlido; Alan Wilson; Ariel Graff-Guerrero
Journal:  Clin Chim Acta       Date:  2015-03-23       Impact factor: 3.786

2.  Dopaminergic dysfunction and psychiatric symptoms in movement disorders: a 123I-FP-CIT SPECT study.

Authors:  Daniela Di Giuda; Giovanni Camardese; Anna Rita Bentivoglio; Fabrizio Cocciolillo; Arianna Guidubaldi; Lorella Pucci; Isabella Bruno; Luigi Janiri; Alessandro Giordano; Alfonso Fasano
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-09-14       Impact factor: 9.236

3.  Chronic coffee consumption and striatal DAT-SPECT findings in Parkinson's disease.

Authors:  Angelo Fabio Gigante; Artor Niccoli Asabella; Giovanni Iliceto; Tommaso Martino; Cristina Ferrari; Giovanni Defazio; Giuseppe Rubini
Journal:  Neurol Sci       Date:  2018-01-23       Impact factor: 3.307

4.  Automatic classification of dopamine transporter SPECT: deep convolutional neural networks can be trained to be robust with respect to variable image characteristics.

Authors:  Markus Wenzel; Fausto Milletari; Julia Krüger; Catharina Lange; Michael Schenk; Ivayla Apostolova; Susanne Klutmann; Marcus Ehrenburg; Ralph Buchert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-08-31       Impact factor: 9.236

5.  Automatic semi-quantification of [123I]FP-CIT SPECT scans in healthy volunteers using BasGan version 2: results from the ENC-DAT database.

Authors:  Flavio Nobili; Mehrdad Naseri; Fabrizio De Carli; Susan Asenbaum; Jan Booij; Jacques Darcourt; Peter Ell; Ozlem Kapucu; Paul Kemp; Claus Svarer; Claus Varer; Silvia Morbelli; Marco Pagani; Osama Sabri; Klaus Tatsch; Livia Tossici-Bolt; Terez Sera; Tierry Vander Borght; Koen Van Laere; Andrea Varrone
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-12-12       Impact factor: 9.236

6.  Robust, fully automatic delineation of the head contour by stereotactical normalization for attenuation correction according to Chang in dopamine transporter scintigraphy.

Authors:  Catharina Lange; Jens Kurth; Anita Seese; Sarah Schwarzenböck; Karen Steinhoff; Bert Umland-Seidler; Bernd J Krause; Winfried Brenner; Osama Sabri; Swen Hesse; Ralph Buchert
Journal:  Eur Radiol       Date:  2015-02-26       Impact factor: 5.315

7.  Semiquantitative Analysis of Dopamine Transporter Scans in Patients With Parkinson Disease.

Authors:  Sule Tinaz; Christopher Chow; Phillip H Kuo; Elizabeth A Krupinski; Hal Blumenfeld; Elan D Louis; George Zubal
Journal:  Clin Nucl Med       Date:  2018-01       Impact factor: 7.794

8.  Estimating endogenous dopamine levels at D2 and D3 receptors in humans using the agonist radiotracer [(11)C]-(+)-PHNO.

Authors:  Fernando Caravaggio; Shinichiro Nakajima; Carol Borlido; Gary Remington; Philip Gerretsen; Alan Wilson; Sylvain Houle; Mahesh Menon; David Mamo; Ariel Graff-Guerrero
Journal:  Neuropsychopharmacology       Date:  2014-05-30       Impact factor: 7.853

9.  Reduction in camera-specific variability in [(123)I]FP-CIT SPECT outcome measures by image reconstruction optimized for multisite settings: impact on age-dependence of the specific binding ratio in the ENC-DAT database of healthy controls.

Authors:  Ralph Buchert; Andreas Kluge; Livia Tossici-Bolt; John Dickson; Marcus Bronzel; Catharina Lange; Susanne Asenbaum; Jan Booij; L Özlem Atay Kapucu; Claus Svarer; Pierre-Malick Koulibaly; Flavio Nobili; Marco Pagani; Osama Sabri; Terez Sera; Klaus Tatsch; Thierry Vander Borght; Koen Van Laere; Andrea Varrone; Hidehiro Iida
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-01-27       Impact factor: 9.236

10.  Impact of age and sex correction on the diagnostic performance of dopamine transporter SPECT.

Authors:  Helen Schmitz-Steinkrüger; Catharina Lange; Ivayla Apostolova; Franziska L Mathies; Lars Frings; Susanne Klutmann; Sabine Hellwig; Philipp T Meyer; Ralph Buchert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-10-31       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.